Erschienen in:
01.02.2024 | editorial
Prostate cancer special—part 2
verfasst von:
Prof. Dr. Shahrokh F. Shariat
Erschienen in:
memo - Magazine of European Medical Oncology
|
Ausgabe 1/2024
Einloggen, um Zugang zu erhalten
Excerpt
I am delighted to present four articles that delve into the forefront of advancements and challenges in prostate cancer management, bringing attention to pivotal developments in the field. Drs. Reiter and Hassler [
1] illuminate the evolving landscape of genetic testing’s role in prostate cancer, emphasizing its significance in guiding treatment decisions and informing preventive strategies for immediate relatives. While guidelines exist, a lack of consensus persists on who should undergo testing, especially among earlier-stage patients lacking a strong familial prostate cancer history. This remains a critical research area with emerging targeted therapies reshaping early lines of intervention. The coming years promise a wealth of evidence guiding cost-effective genetic testing and treatment strategies. …